Pharmaceuticals

Biologics CDMO Market Expansion Outlook: $41.53 Billion by 2029 Forecast

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Forecasted Market Size Estimates For The Biologics CDMO Market Between 2025 And 2029?

The biologics CDMO market has experienced substantial expansion in recent years. Its value is projected to rise from $21.3 billion in 2024 to $24.15 billion in 2025, achieving a compound annual growth rate (CAGR) of 13.4%. The factors contributing to its historical growth include an increase in biologics development, the advantages of cost efficiency and flexibility, an emphasis on core competencies, adherence to regulatory compliance and quality assurance, and the globalization of pharmaceutical supply chains.

The biologics CDMO market size is anticipated to expand significantly in the coming years, reaching $41.53 billion by 2029, with a compound annual growth rate (CAGR) of 14.5%. This growth during the forecast period is driven by factors such as the increasing demand for biologic therapies, the introduction of biosimilars and biobetters, greater investments in biomanufacturing infrastructure, a shift towards outsourcing complex processes, a strong focus on supply chain resilience and risk mitigation, regulatory harmonization, and expedited approvals. Key trends expected in the forecast period involve expanding capabilities to offer comprehensive end-to-end solutions, the adoption of single-use technologies, the integration of continuous manufacturing processes, and the emergence of specialized CDMOs.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14056&type=smp

Which Drivers Are Supporting Growth Of The Biologics CDMO Market?

The increasing need for cell and genetic therapy is anticipated to boost the expansion of the biologic CDMO market in the future. These therapies represent cutting-edge medical methods that employ live cells or genetic material to target fundamental disease origins at a cellular or genetic scale, offering prospective solutions for illnesses resistant to conventional drugs or deemed incurable. The growing interest in cell and gene therapy stems from their capacity to provide novel disease treatments by tackling core genetic or cellular issues. Biologic CDMOs offer specialized knowledge in managing live cells, viral vectors, and genetic material, ensuring the secure and effective manufacturing of cell and gene therapies. They also support biopharmaceutical firms through regulatory complexities and technical hurdles, thus accelerating the transition from laboratory research to clinical implementation. As an illustration, The American Society of Gene & Cell Therapy (ASGCT), a leading US professional body, reported in January 2023 that the pipeline for gene, cell, and RNA therapy expanded by 7% in 2022, accumulating 3,726 therapies under development. Among these, 55% were gene therapies, 22% were non-genetically modified cell therapies, and 23% were RNA therapies. Consequently, the increased demand for cell and genetic therapy is a key factor propelling the expansion of the biologic CDMO market.

What Are The Different Segment Classifications Within The Biologics CDMO Market?

The biologics cdmo market covered in this report is segmented –

1) By Cell Type: Mammalian, Non-Mammalian

2) By Product Type: Biologics, Biosimilars

Subsegments:

1) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cells

2) By Non-Mammalian: Yeast Cells, Bacterial Cells, Insect Cells, Other Non-Mammalian Cells

How Are Trends Influencing The Biologics CDMO Market?

Leading companies in the biologics CDMO market are developing advanced technological solutions, such as new cell lines, to enhance the efficiency and capabilities of biopharmaceutical development and manufacturing. This technology produces therapeutic antibodies with improved potency, addressing challenges in immunotherapy research and development. For instance, in November 2023, Lonza Group, a Switzerland-based manufacturing company specializing in the pharmaceutical and biotechnology sectors, launched GS Effex cell lines. These are designed to produce antibodies that are 100% free of fucose, a sugar molecule, and demonstrate increased potency without compromising other performance attributes. This innovation helps overcome immunotherapy research and development challenges related to the necessity for antibody therapeutics to enhance potency. It represents a stable, scalable, and productive cell line, offering a solution for therapeutic development from discovery-stage research through to commercial manufacturing.

Which Key Market Players Are Investing In Expansion And Innovation Of Biologics CDMO Market?

Major companies operating in the biologics CDMO market are AbbVie Inc., Thermo Fisher Scientific Inc., Novartis AG, Evonik Industries AG, Sandoz International GmbH, ICON PLC, Grifols SA, Lonza Group Ltd., Boehringer Ingelheim International GmbH, Catalent Inc., JSR Corp., Parexel International Corporation, WuXi Biologics (Cayman) Inc., Samsung Biologics Co. Ltd., Emergent BioSolutions Inc., Rentschler Biopharma SE, FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Binex Co. Ltd., Bora Pharmaceuticals Co. Ltd, 3P Biopharmaceuticals s.l.u, JRS Pharma LP, J Rettenmaier and SOHNE GmbH and Co KG, Kemwell Biopharma Pvt. Ltd., Cytovance Biologics, AGC Biologics, Shenzhen Hepalink Pharmaceutical Co. Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report

Which Geographies Are Emerging As Strong Markets For The Biologics CDMO Industry?

North America was the largest region in the biologics CDMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics CDMO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Biologics CDMO Market Report:

https://www.thebusinessresearchcompany.com/customise?id=14056&type=smp

Browse Through More Reports Similar to the Global Biologics CDMO Market 2025, By The Business Research Company

Biodegradable Plastics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biodegradable-plastics-global-market-report

Soap And Other Detergents Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/soap-and-other-detergents-global-market-report

Detergent Chemicals Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/detergent-chemicals-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795